{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T22:44:06Z","timestamp":1794437046197,"version":"4.9.1"},"reference-count":19,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,6]]},"DOI":"10.1097\/01.aog.0000450757.18294.cf","type":"journal-article","created":{"date-parts":[[2014,5,22]],"date-time":"2014-05-22T07:41:10Z","timestamp":1400744470000},"page":"1394-1397","source":"Crossref","is-referenced-by-count":132,"title":["Committee Opinion No. 601"],"prefix":"10.1097","volume":"123","member":"276","reference":[{"key":"R1-50-20210126","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/j.1749-6632.1994.tb21761.x","article-title":"Tamoxifen and endometrial cancer.","volume":"734","author":"Sismondi","year":"1994","journal-title":"Ann N Y Acad Sci"},{"key":"R2-50-20210126","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1016\/S0140-6736(94)90747-1","article-title":"Gynaecological monitoring during tamoxifen therapy.","volume":"344","author":"Bissett","year":"1994","journal-title":"Lancet"},{"key":"R3-50-20210126","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1093\/jnci\/86.7.527","article-title":"Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14.","volume":"86","author":"Fisher","year":"1994","journal-title":"J Natl Cancer Inst"},{"key":"R4-50-20210126","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1006\/gyno.1994.1271","article-title":"Tamoxifen use in breast cancer patients who subsequently develop corpus cancer is not associated with a higher incidence of adverse histologic features.","volume":"55","author":"Barakat","year":"1994","journal-title":"Gynecol Oncol"},{"key":"R5-50-20210126","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1200\/JCO.1993.11.3.485","article-title":"High-grade endometrial carcinoma in tamoxifen-treated breast cancer patients.","volume":"11","author":"Magriples","year":"1993","journal-title":"J Clin Oncol"},{"key":"R6-50-20210126","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/S0140-6736(12)61963-1","article-title":". Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Adjuvant Tamoxifen: Longer Against Shorter (ATLAS) Collaborative Group published erratum appears in Lancet 2013;381:804.","volume":"381","author":"Davies","year":"2013","journal-title":"Lancet"},{"key":"R7-50-20210126","doi-asserted-by":"crossref","first-page":"2758","DOI":"10.1200\/JCO.2002.20.11.2758","article-title":". Association of tamoxifen and uterine sarcoma.","volume":"20","author":"Wickerham","year":"2002","journal-title":"J Clin Oncol"},{"key":"R8-50-20210126","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.ygyno.2003.12.029","article-title":"Surveillance, epidemiology, and end results analysis of 2677 cases of uterine sarcoma 1989-1999.","volume":"93","author":"Brooks","year":"2004","journal-title":"Gynecol Oncol"},{"key":"R9-50-20210126","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0305-7372(78)80017-6","article-title":"Tamoxifen in advanced breast cancer.","volume":"5","author":"Mouridsen","year":"1978","journal-title":"Cancer Treat Rev"},{"key":"R10-50-20210126","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1093\/jnci\/90.18.1371","article-title":". Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study.","volume":"90","author":"Fisher","year":"1998","journal-title":"J Natl Cancer Inst"},{"key":"R11-50-20210126","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1006\/gyno.1997.4739","article-title":"Comparison of endometrial changes among symptomatic tamoxifen-treated and nontreated premenopausal and postmenopausal breast cancer patients.","volume":"66","author":"Cheng","year":"1997","journal-title":"Gynecol Oncol"},{"key":"R12-50-20210126","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1046\/j.1469-0705.1995.06020116.x","article-title":". Changes mimicking endometrial neoplasia in postmenopausal, tamoxifen-treated women with breast cancer: a transvaginal Doppler study.","volume":"6","author":"Achiron","year":"1995","journal-title":"Ultrasound Obstet Gynecol"},{"key":"R13-50-20210126","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1023\/A:1005820115535","article-title":". Tamoxifen and the endometrium: findings of pelvic ultrasound examination and endometrial biopsy in asymptomatic breast cancer patients.","volume":"47","author":"Bertelli","year":"1998","journal-title":"Breast Cancer Res Treat"},{"key":"R14-50-20210126","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/S0090-8258(03)00441-4","article-title":". Prospective longitudinal study of ultrasound screening for endometrial abnormalities in women with breast cancer receiving tamoxifen.","volume":"91","author":"Fung","year":"2003","journal-title":"Gynecol Oncol"},{"key":"R15-50-20210126","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1200\/JCO.1999.17.7.2050","article-title":"Investigation of endometrial abnormalities in asymptomatic women treated with tamoxifen and an evaluation of the role of endometrial screening.","volume":"17","author":"Love","year":"1999","journal-title":"J Clin Oncol"},{"key":"R16-50-20210126","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.ygyno.2004.06.033","article-title":"The value of sonohysterography in the prediction of endometrial pathologies in asymptomatic postmenopausal breast cancer tamoxifen-treated patients.","volume":"94","author":"Markovitch","year":"2004","journal-title":"Gynecol Oncol"},{"key":"R17-50-20210126","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0029-7844(97)00591-7","article-title":"Uterine side effects of tamoxifen: a need for systematic pretreatment screening.","volume":"91","author":"Berliere","year":"1998","journal-title":"Obstet Gynecol"},{"issue":"suppl 4","key":"R18-50-20210126","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1016\/S0959-8049(00)00217-3","article-title":"Identification of women at high risk of developing endometrial cancer on tamoxifen.","volume":"36","author":"Berliere","year":"2000","journal-title":"Eur J Cancer"},{"key":"R19-50-20210126","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/S0301-2115(01)00516-4","article-title":"Endometrial disorders in 406 breast cancer patients on tamoxifen: the case for less intensive monitoring.","volume":"101","author":"Vosse","year":"2002","journal-title":"Eur J Obstet Gynecol Reprod Biol"}],"container-title":["Obstetrics & Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/01.AOG.0000450757.18294.cf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,10]],"date-time":"2021-11-10T09:33:10Z","timestamp":1636536790000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00006250-201406000-00050"}},"subtitle":["Tamoxifen and Uterine Cancer"],"short-title":[],"issued":{"date-parts":[[2014,6]]},"references-count":19,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.1097\/01.aog.0000450757.18294.cf","relation":{},"ISSN":["0029-7844"],"issn-type":[{"value":"0029-7844","type":"print"}],"subject":[],"published":{"date-parts":[[2014,6]]}}}